---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-003036"
form_type: "8-K"
ticker: "PLX"
cik: "0001006281"
company_name: "Protalix BioTherapeutics, Inc."
filed_at: "2025-03-17T23:59:59+00:00"
generated_at: "2026-05-24T14:55:00.400723+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Protalix FY 2024: Record product revenue $53M (+31%), net income $2.9M; debt-free

## Summary
- Revenue from goods $53.0M (+31% YoY), driven by Chiesi sales (+$11.8M); total revenue $53.4M vs $65.5M in 2023.
- Net income $2.9M ($0.04/sh diluted) vs $8.3M ($0.12/sh basic) in 2023; lower due to absence of $20M milestone.
- Cash $34.8M; convertible notes fully repaid Sep 2024; no warrants remaining after March 2025 expiration.
- PRX-115 (gout) phase I completed; phase II expected H2 2025; EMA validated less frequent dosing for pegunigalsidase alfa.

## SEC filing metadata
- accession: 0001558370-25-003036
- form_type: 8-K
- ticker: PLX
- cik: 0001006281
- company_name: Protalix BioTherapeutics, Inc.
- filed_at: 2025-03-17T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006281/000155837025003036/0001558370-25-003036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006281/000155837025003036/plx-20250317x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-003036
- JSON: https://secwatch.observer/filing/0001558370-25-003036.json
- Plain text: https://secwatch.observer/filing/0001558370-25-003036.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.